Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arnold Lee

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
Drugs|April 16, 2025
Crinecerfont: First ApprovalArnold Lee
Drugs|April 3, 2025
Acoramidis: First ApprovalArnold Lee
Drugs|September 25, 2025
Onradivir: First ApprovalArnold Lee
Targeted Oncology|December 2, 2022
Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung CancerArnold Lee
Drugs|July 7, 2022
Serplulimab: First ApprovalArnold Lee
Drugs|March 1, 2023
Nadofaragene Firadenovec: First ApprovalArnold Lee
Drugs|March 22, 2021
Ansuvimab: First ApprovalArnold Lee
Targeted Oncology|October 12, 2021
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian CancerArnold Lee
Drugs|September 1, 2021
Correction to: Fuzuloparib: First ApprovalArnold Lee
Targeted Oncology|December 15, 2021
MYL-1402O: A Bevacizumab BiosimilarArnold Lee
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
Drugs|April 16, 2025
Crinecerfont: First ApprovalArnold Lee
Drugs|April 3, 2025
Acoramidis: First ApprovalArnold Lee
Drugs|September 25, 2025
Onradivir: First ApprovalArnold Lee
Targeted Oncology|December 2, 2022
Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung CancerArnold Lee
Drugs|July 7, 2022
Serplulimab: First ApprovalArnold Lee
Drugs|March 1, 2023
Nadofaragene Firadenovec: First ApprovalArnold Lee
Drugs|March 22, 2021
Ansuvimab: First ApprovalArnold Lee
Targeted Oncology|October 12, 2021
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian CancerArnold Lee
Drugs|September 1, 2021
Correction to: Fuzuloparib: First ApprovalArnold Lee
Targeted Oncology|December 15, 2021
MYL-1402O: A Bevacizumab BiosimilarArnold Lee
Pageof 10